Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Balversa Launched in Japan as 1st Genetically Targeted Drug for Bladder Cancer: J&J
July 17, 2025
- Towa Resumes Packaging Operations at Fire-Hit Yamagata Facility
July 17, 2025
- Nobelpharma’s Pediatric Sleep Aid Melatonin Wins Nod in China
July 17, 2025
- Fire Breaks Out at Towa’s Yamagata Plant, Production Halted at One Building
July 16, 2025
- JCR, Acumen Hook Up to Develop BBB-Penetrating Alzheimer’s Therapy
July 16, 2025
- Otsuka Bags Autoimmune Antibody Drug from Swedish Biotech
July 16, 2025
- Global Pharma Market Surges 9% to US$1.6 Trillion in 2024, Ozempic Overtakes Humira: IQVIA
July 16, 2025
- Asahi Kasei Sharpens Acquisition Focus in Pharma Biz as Envarsus LOE Looms
July 15, 2025
- MSD Seeks Japan Nod for RSV Antibody Clesrovimab
July 15, 2025
- Takeda’s OX2R Agonist Makes Mark in PIII NT1 Trials, US Filing Planned in FY2025
July 15, 2025
- FDA Rejects Capricor/Nippon Shinyaku’s DMD Cell Therapy, Seeking More Data
July 15, 2025
- Eisai Launches Gout Drug Urece in China
July 15, 2025
- Japan’s Feliqs to Relocate Headquarters to US, Launch PIb for ROP Drug
July 15, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Merck Japan Joins Hands with Kawasaki City Incubator to Support Startups
July 15, 2025
- Taking on Solid Tumors - 8: Amgen Gains Early Lead with TCE Imdelltra, More Assets in the Pipeline
July 14, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Toho, Teijin, and Itochu to Jointly Build Regenerative Medicine Ecosystem
July 14, 2025
- Solasia Invests in Sweden’s Isofol as Colorectal Cancer Trials Resume
July 14, 2025
- All Three PPI Switch OTCs Approved following MHLW Panel OK
July 14, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…